- Report
- January 2019
- 35 Pages
Global
From €971EUR$1,000USD£838GBP
Sivextro (tedizolid phosphate) is an antibiotic used to treat certain bacterial infections. It belongs to a class of antibiotics called oxazolidinones, which work by stopping the growth of bacteria. Sivextro is used to treat skin and soft tissue infections caused by certain bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is also used to treat pneumonia caused by certain bacteria. Sivextro is available in tablet and intravenous (IV) forms.
Sivextro is marketed by Merck & Co., Inc. in the United States and by Shionogi & Co., Ltd. in Japan. It is also available in other countries through various generic manufacturers.
The Sivextro market is a rapidly growing segment of the antibiotics market. It is used to treat a variety of bacterial infections, including skin and soft tissue infections and pneumonia. The increasing prevalence of antibiotic-resistant bacteria is driving the growth of the Sivextro market.
Companies in the Sivextro market include Merck & Co., Inc., Shionogi & Co., Ltd., and various generic manufacturers. Show Less Read more